Published on
September 1, 2026
- 10:00 GMT
BLR Bio New Research - Therapeutic has Potential to Address Cancer Drug Resistance Through YAP Translocation Modulation
Opportunities for use in combination with immunotherapies (e.g. PD1), KRAS inhibitors, ADCs and chemotherapy NORTH CHICAGO, IL, UNITED STATES, September 1, 2026 /EINPresswire.com/ -- BLR Bio LLC announced new findings demonstrating the potential of its …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
